Clinical Trials · NCT00042458

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

Name: Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Pramlintide

Phase: Phase 3
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 296
Start date: Apr 2002
Locations: 33 sites, United States
Primary endpoint: - To investigate the safety of pramlintide treatment employing dose titration upon initiation of pramlintide followed by insulin dose optimization in subjects with type 1 diabetes.

View Pramlintide compound reference